The overall dynamics of the Vasomotor Symptoms market size is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period of 2021–2030

DelveInsight’s Vasomotor Symptoms (Hot Flashes/Night Sweats) market report offers comprehensive coverage of the current treatment practices, emerging drugs for Hot flashes/Night sweats and their market share of the individual therapies, current and forecasted Vasomotor symptoms market size from 2018 to 2030 segmented into 7MM (the United States, EU5 (Germany, Spain, Italy, France, and the UK), and Japan).

Some of the Key Findings from the Vasomotor Symptoms Market Report

• According to DelveInsight’s Vasomotor Symptoms epidemiology insights, the total prevalent population was estimated to be 18,926,632 in the United States in 2018, among which the highest cases were of mild cases followed by moderate and severe Vasomotor Symptoms cases.
• Among the EU5 countries, Germany had the highest Vasomotor Symptoms prevalent population while Spain had the lowest in 2018.
• Several pharmaceutical companies, including Mithra Pharmaceuticals, Astellas Pharma, Bayer, Fervent Pharmaceuticals, and others, are developing Hot Flashes treatment therapies that are expected to enter the US market by 2030.
• Key pipeline therapies in the Vasomotor Symptoms market include Donesta, Fezolinetant, Elinzanetant, FP-101, and several others.
• Donesta (Mithra Pharmaceuticals) is a hormone therapy (HT) candidate based on E4 for the treatment of Vasomotor Menopausal Symptoms (VMS). It is currently in Phase III clinical trials for the treatment of Hot Flashes.
• Fezolinetant developed by Astellas Pharma is a proprietary, oral, small-molecule discovered to treat women’s health disorders, and it is expected to have the greatest impact on the nonhormonal therapeutic market of Vasomotor Symptoms associated with menopause.
• Elinzanetant/BAY3427080/NT-814 is an orally administered, potent, and selective small-molecule dual antagonist of both the neurokinin-1 and 3 receptors that Bayer is developing as a therapy for a variety of women’s health issues.

For a better understanding of the disease, request a sample @ Vasomotor Symptoms Market Research

The Vasomotor Symptoms market report also discusses current Vasomotor Symptoms treatment practices/algorithms, Vasomotor Symptoms market drivers, Vasomotor Symptoms market barriers, and unmet medical needs in order to curate the best opportunities. It evaluates the Vasomotor Symptoms market’s underlying potential.

Vasomotor Symptoms: Overview

Vasomotor Symptoms are the most commonly reported menopausal symptoms. These symptoms, also known as hot flashes, are characterized by a sudden increase in blood flow, often to the face, neck, and chest, which causes extreme heat and profuse sweating. VMS is a type of temperature dysfunction caused by changes in gonadal hormones. Core body temperature (CBT) normally stays within a narrow range, oscillating with daily circadian rhythms.

Vasomotor Symptoms Epidemiology Segmentation

The Vasomotor Symptoms report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

• Vasomotor Symptoms Total Prevalent Pool
• Vasomotor Symptoms Severity-Specific Prevalent Pool

Get the complete epidemiology analysis @ Vasomotor Symptoms Associated with Menopause

Vasomotor Symptoms Treatment Landscape

There are two types of treatment available for Vasomotor Symptoms- Hormonal Therapies and Non-Hormonal Therapies. Premarin (Pfizer), Menest (Pfizer), Alora (Allergan), Climara Pro (Bayer Healthcare), MINIVELLE (Noven Therapeutics), Evamist (Perrigo Pharma), Elestrin (DPT Laboratories), and Bijuva (TherapeuticsMD) are some of the FDA approved Hormonal Therapies for the treatment of Vasomotor Symptoms.

The Non-Hormonal therapies used for Vasomotor Symptoms treatment include antidepressants, gabapentin, and clonidine. Brisdelle is the first and only non-hormonal antidepressant approved for the treatment of Vasomotor Symptoms.

Vasomotor Symptoms Market

• The Vasomotor Symptoms associated with menopause market size was found to be USD 1,775.8 million in the 7MM in 2018.
• The United States accounted for 61% USD of the total Vasomotor Symptoms market share among the 7MM countries in 2018. 
• Among the EU5 countries, the United Kingdom has the highest Vasomotor Symptoms market size in 2018.
• The launch of Donesta, Fezolinetant, Elinzanetant, FP-101, and others are anticipated to provide a major push to the growth of the Vasomotor Symptoms associated with menopause market size during the forecast period 2021-30 in the 7MM.

Vasomotor Symptoms Pipeline Therapies and Key Companies 

• Fezolinetant: Astellas Pharma
• Elinzanetant: Bayer
• FP-101: Fervent Pharmaceuticals
• Donesta: Mithra Pharmaceuticals 

For more information on the pipeline therapies and companies, visit Vasomotor Symptoms Treatment Drugs

Vasomotor Symptoms Market Drivers

• Increasing awareness
• Rising emerging therapies

Vasomotor Symptoms Market Barriers

• Generic nature of the market
• Limited understanding of Pathophysiology

Scope for the Report

Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)

Study Period: 2018-30

Vasomotor Symptoms Key Companies: Mithra Pharmaceuticals, Astellas Pharma, Bayer, Fervent Pharmaceuticals, among others. 

Vasomotor Symptoms Key Pipeline Therapies: Donesta, Fezolinetant, Elinzanetant, FP-101, and others.

Vasomotor Symptoms Segmentation: By Geography, Vasomotor Symptoms drugs

Analysis: Comparative and conjoint analysis of  Vasomotor Symptoms emerging therapies

Tools Used: SWOT Analysis

Case Studies

KOL’s Views

Analyst’s Views

Table of Contents

Know more about report offerings @ Vasomotor Symptoms Market Outlook

Related Reports

Hot Flashes Market 

Get comprehensive historical and forecast analysis of Hot Flashes Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Mithra Pharmaceuticals, Astellas Pharma, Bayer, Fervent Pharmaceuticals, Sojournix, among others.

Post Menopausal Osteoporosis Market 

DelveInsight’s “Post Menopausal Osteoporosis – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Post Menopausal Osteoporosis, historical and forecasted epidemiology as well as the Post Menopausal Osteoporosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Bacterial Vaginosis Market

DelveInsight’s “Bacterial Vaginosis – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Bacterial Vaginosis, historical and forecasted epidemiology as well as the Bacterial Vaginosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Dysmenorrhea Market

Get comprehensive historical and forecast analysis of Dysmenorrhea Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as AbbVie, Neurosciences Biosciences, Nobelpharma, ASKA Pharmaceutical, ObsEva, Myovant Sciences/Takeda, Pure Green, among others.

Endometriosis Market

DelveInsight’s “Endometriosis – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Endometriosis, historical and forecasted epidemiology as well as the Endometriosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Epithelial Ovarian Cancer Market

DelveInsight’s “Epithelial Ovarian Cancer Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Epithelial Ovarian Cancer, historical and forecasted epidemiology as well as the Epithelial Ovarian Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Polycystic Ovarian Syndrome Market

Get comprehensive historical and forecast analysis of Polycystic Ovarian Syndrome Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Zydus Discovery DMCC, Spruce Biosciences, Kindex Pharmaceuticals, among others.

Postmenopausal Vaginal Atrophy Market

DelveInsight’s “Postmenopausal Vaginal Atrophy – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Postmenopausal Vaginal Atrophy, historical and forecasted epidemiology as well as the Postmenopausal Vaginal Atrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Postpartum Depression Market

Get comprehensive historical and forecast analysis of Postpartum Depression Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Sage Therapeutics, among others.

Uterine fibroids Market

DelveInsight’s “Uterine fibroids – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Uterine fibroids, historical and forecasted epidemiology as well as the Uterine fibroids market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Get in touch with our Business executive for Competitive Insights, M&A and Due Diligence Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. 

Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us 

Sandeep Joshi 

info@delveinsight.com 

+1(919)321-6187 

www.delveinsight.com

Connect With Us at:

LinkedIn | Facebook | Twitter

Contact Information: